The Spanish SOLTI-1716 TATEN trial sees favourable responses and survival when combining pembrolizumab and paclitaxel in HER2-enriched or basal-like tumours....
A phase IIa trial evaluates ceralasertib, an oral ATR inhibitor, in advanced tumours with ATM alterations. Objective responses were limited, although the safety profile was manageable....
A genomic analysis of the NeoTRIPaPDL1 trial identifies tumour features and early changes during treatment associated with response to neoadjuvant chemoimmunotherapy....
A phase I/II trial evaluates the first conditionally activated antibody-drug conjugate against CD166, with clinical and translational activity across several tumour types, including breast cancer....
A translational analysis of the GEICAM PEARL trial shows that blood thymidine kinase is a prognostic marker and that its early changes provide treatment-specific information....
In the phase III PEARL trial, combining palbociclib with endocrine therapy did not improve progression-free survival versus capecitabine, although it offered a better safety profile and quality of lif...